The neuroscience specialist H. Lundbeck A/S has raised its profit forecast for 2018 on the back of revenue and earnings gains in the first nine months and a significant improvement in its operating margin.
“Lundbeck remains on track to deliver the best-ever financial results, creating the foundation to work to strengthen the pipeline for future growth,” said Deborah Dunsire, the company’s new chief executive. Dr Dunsire joined Lundbeck on 1 September having previously managed biopharmaceutical companies in the areas of oncology and central nervous system disorders.